On Wednesday, May 20, the Foundation for the National Institutes of Health (FNIH) will bring together leaders from biomedical science, the biotech and pharmaceutical industries, philanthropy and business, for the 2015 FNIH Award Ceremony and presentation of the Lurie Prize in Biomedical Sciences.
In the first donation of its kind for the Foundation for the National Institutes of Health (FNIH), the John & Marcia Goldman Foundation has awarded $25,000 to support Ebola research in West Africa conducted by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health.
The Lung-MAP trial, a multi-drug, multi-sub-study, biomarker-driven clinical trial for patients with advanced squamous cell lung cancer, that launched on June 16th 2014, today announced that it has expanded to an additional 169 locations throughout the United States. They join 85 locations that have been participating in the trial since the June launch. All locations can be found here: http://www.lung-map.org/locations
A unique public-private collaboration among the National Cancer Institute (NCI), part of the National Institutes of Health, SWOG Cancer Research, Friends of Cancer Research (Friends), the Foundation for the National Institutes of Health (FNIH), five pharmaceutical companies (Amgen, Genentech, Pfizer, AstraZeneca, and AstraZeneca’s global biologics R&D arm, MedImmune), and Foundation Medicine today announced the initiation of the Lung Cancer Master Protocol (Lung-MAP) trial.
Low muscle mass and weakness are important contributors to sarcopenia, a common and potentially disabling condition in older adults. Diagnostic criteria have been proposed, but no consensus yet exists.
The Foundation for the National Institutes of Health (FNIH) has selected Jennifer Doudna, Ph.D., a Professor from the University of California, Berkeley, as the second winner of its Lurie Prize in the Biomedical Sciences. Doudna, a Howard Hughes Investigator and Professor of Biochemistry, Biophysics and Structural Biology, will be presented the Lurie Prize medal and a $100,000 honorarium on May 20 in Washington, D.C.
The I-SPY 2 TRIAL, a randomized phase II clinical trial for breast cancer launched through a unique partnership with the Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium and sponsored by QuantumLeap Healthcare Collaborative has graduated the first two drugs from its innovative, multidrug standing platform trial.
The National Institutes of Health has selected eight projects to receive support to answer some of the most fundamental problems on traumatic brain injury, including understanding long-term effects of repeated head injuries and improving diagnosis of concussions.
The Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium announced today the launch of a three-year study to track the progression of osteoporosis more precisely and pave the way for more effective treatments. The study, which utilizes data from existing academic and clinical trials, is designed to establish the validity of specific imaging and biochemical markers for bone health.
The Foundation for the National Institutes of Health, in association with the Geoffrey Beene Foundation Alzheimer’s Initiative, today announced the top four winners of the preliminary round of the first-ever challenge to identify male/female differences in Alzheimer’s Disease (AD).